Bringing clarity to quality
The payer paradigm is shifting to one that is focused on defining value as the balance of cost and quality. Turn to Xcenda in this evolving environment for evidence that demonstrates the clinical impact of products, the link to quality measures, and how these will drive the future of product lifecycle planning. Let us help you navigate through the growing policies and measures that affect your products to demonstrate quality outcomes that matter most.
Develop a quality strategy that meets your needs. Strategic and tactical offerings include:
Quality planning roadmaps and workshops
Therapeutic area quality task forces
Landscape assessment and monitoring of measures and metrics
Quality and pharmacoeconomic evidence generation
Triple Aim-focused value proposition development
Quality market research
Metric and program public comment opportunities
Field training and education
Payment reform and quality workshops
Meet the experts
Michelle Friedman, MPH
Michelle is associate director of Global Health Economics and Outcomes Research at Xcenda. In this role, she leads health economics and strategic consulting engagements that help manufacturers demonstrate, realize, and communicate product value to key stakeholders. Her work includes the development of value propositions and evidence-generation planning for individual products and therapeutic portfolios. She also has expertise in leading and managing advisory boards, literature reviews, pharmacoeconomic models, retrospective database studies, and dossiers along with extensive background in academic research.
Influence of quality metrics on formulary coverage decisions
How are payers thinking about quality as part of their coverage decision-making process? Xcenda experts conducted a study to understand the influence of quality metrics on formulary coverage and evaluate the importance of aligning manufacturer labels and evidence with quality metrics.